Evidence map›Paper›PMID 27036118›Full record

ArticleArthritis research & therapy2016

Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase.

Elena Gonzalo-Gil, María J Pérez-Lorenzo, María Galindo, Rafael Díaz de la Guardia, Belén López-Millán, Clara Bueno, Pablo Menéndez, José L Pablos, Gabriel Criado

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  5. Review
  6. Cell-based therapies for the treatment of rheumatoid arthritis.Immunity, inflammation and disease · 2023
    Review
  7. Article
  8. Article
  9. Translating MSC Therapy in the Age of Obesity.Frontiers in immunology · 2022
    Review
  10. Review
  11. Review
  12. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  13. Review
  14. Review
  15. Stability of housekeeping genes in inflamed joints of spontaneous and collagen-induced arthritis in DBA/1 mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elena Gonzalo-GilInflammatory and Autoimmune Diseases Group, Hospital 12 de Octubre Research Institute, Madrid, Spain.
María J Pérez-LorenzoInflammatory and Autoimmune Diseases Group, Hospital 12 de Octubre Research Institute, Madrid, Spain.
María GalindoInflammatory and Autoimmune Diseases Group, Hospital 12 de Octubre Research Institute, Madrid, Spain.
Rafael Díaz de la GuardiaJosep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain.
Belén López-MillánJosep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain.
Clara BuenoJosep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain.
Pablo MenéndezJosep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain.
José L PablosInflammatory and Autoimmune Diseases Group, Hospital 12 de Octubre Research Institute, Madrid, Spain.
Gabriel CriadoInflammatory and Autoimmune Diseases Group, Hospital 12 de Octubre Research Institute, Madrid, Spain. gcriado@h12o.es.ORCID http://orcid.org/0000-0003-4824-0890
Research Institute Hospital 12 de Octubre · ESJosep Carreras Leukaemia Research Institute · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe immunosuppressive and anti-inflammatory properties of mesenchymal stromal cells (MSC) have prompted their therapeutic application in several autoimmune diseases, including rheumatoid arthritis. Adult MSC are finite and their clinical use is restricted by the need for long-term expansion protocols that can lead to genomic instability. Inhibition of Smad2/3 signaling in human pluripotent stem cells (hPSC) provides an infinite source of MSC that match the phenotype and functional properties of adult MSC. Here, we test the therapeutic potential of hPSC-MSC of embryonic origin (embryonic stem cell-derived mesenchymal stromal cells, hESC-MSC) in the experimental model of collagen-induced arthritis (CIA).

methodsCIA was induced in DBA/1 mice by immunization with type II collagen (CII) in Complete Freund's Adjuvant (CFA). Mice were treated with either a single dose (10(6) cells/mouse) of hESC-MSC on the day of immunization (prophylaxis) or with three doses of hESC-MSC every other day starting on the day of arthritis onset (therapy). Arthritis severity was evaluated daily for six weeks and ten days, respectively. Frequency of Treg (FoxP3(+)), Th1 (IFNγ(+)) and Th17 (IL17(+)) CD4(+) T cells in inguinal lymph nodes (ILN) was quantified by flow cytometry. Serum levels of anti-CII antibodies were determined by ELISA. Detection of hESC-MSC and quantification of murine and human indoleamine 2,3 dioxygenase (IDO1) expression was performed by quantitative real-time PCR. Statistical differences were analyzed by ANOVA and the Mann-Whitney U test.

resultsAdministration of hESC-MSC to mice with established arthritis reduced disease severity compared to control-treated mice. Analysis of CD4 T cell populations in treated mice showed an increase in FoxP3(+) Treg and IFNγ(+) Th1 cells but not in Th17 cells in the ILN. Anti-CII antibody levels were not affected by treatment. Migration of hESC-MSC to the ILN in treated mice was associated with the induction of murine IDO1.

conclusionTreatment with hESC-MSC ameliorates CIA by inducing IFNγ(+) Th1 cells and IDO1 in the host. Thus, hESC-MSC can provide an infinite cellular source for treatment of rheumatoid arthritis.

Indexed as

Arthritis, ExperimentalAnimalsArthritis, RheumatoidCD4-Positive T-LymphocytesFlow CytometryHeterograftsHuman Embryonic Stem CellsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, Inbred DBAReal-Time Polymerase Chain ReactionIDO1 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseArthritisCytokinesHuman embryonic stem cell-derived mesenchymal stromal cellsIndoleamine 2,3 dioxygenaseT cells

Identifiers

PMID27036118
PMCPMC4818397
OpenAlexW2328159426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.